Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting
Mary Jane Minkin, MD, FACOG, MSCP, discusses key takeaways from The Menopause Society 2023 Annual Meeting, held in Philadelphia, Pennsylvania from September 27-30.
Contemporary OB/GYN:
Can you explain your highlights or takeaways from The Menopause Society 2023 Annual Meeting?
Mary Jane Minkin, MD, FACOG, MSCP:
There are a lot of highlights from this meeting. Actually, for me, it may sound odd, but the highlight occurred pretty much early in the meeting, because we Susan Dominus as one of our keynote speakers, who wrote a, I think, landmark article in the Sunday, New York Times Magazine last February. The title was "Women Have Been Misled About Menopause," and that has really revolutionized, at least I think it has, women's interest and attitudes about menopause. I have had more calls this summer in the spring and summer than I ever have about menopausal topics. People are just really interested in it and women were really moved by this article, and she gave a fabulous talk. She got a standing ovation from the assembled multitudes in the audience and we've been chatting about it a lot, basically talking about the effect of transitions from estrogen and hormones for everybody to hormones to nobody after the Women's Health Initiative (WHI) with a resurgence of interest in them, and resurgence of education, we hope about hormonal therapy. So it's been a very interesting meeting that way, and a lot of other wonderful science as well.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 3rd 2021In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Listen
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.
Read More
